Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023GlobeNewsWire • 10/25/23
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023GlobeNewsWire • 09/27/23
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/31/23
Verrica Issues Statement in Support of FDA's Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum ContagiosumGlobeNewsWire • 08/23/23
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy MeetingGlobeNewsWire • 08/10/23
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's (AAD) 2023 Innovation Academy MeetingGlobeNewsWire • 08/03/23
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMedGlobeNewsWire • 07/26/23
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ETGlobeNewsWire • 07/24/23
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum ContagiosumGlobeNewsWire • 07/21/23
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New YorkGlobeNewsWire • 05/31/23
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/10/23
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell CarcinomaGlobeNewsWire • 04/12/23
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/11/23
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial ResultsGlobeNewsWire • 03/06/23
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 02/28/23
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 02/27/23
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 02/21/23
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 01/24/23
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma SolutionsGlobeNewsWire • 01/04/23